AlphaStocks
6.0
Consider Buy

GILEAD SCIENCES, INC. (GILD)

Health Care / Biotechnology

S&P 500

$123.63

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 4 of 5 models — moderate confidence

#264out of 1123 in Health Care

Is GILEAD SCIENCES, INC. a Good Investment in 2026?

GILEAD SCIENCES, INC. (GILD) scores 6.0 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates GILEAD SCIENCES, INC. as Strong (7/9). However, the Graham model rates it Caution — Significantly above fair value. GILEAD SCIENCES, INC. currently trades below its estimated fair value of $127, suggesting potential upside. GILEAD SCIENCES, INC. ranks #264 out of 1123 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E18.2ROE38.5Market Cap155BDiv Yield2.4

Estimated Fair Value

$126.612% below

Trading near estimated fair value.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

7/9

Buffett

Strong

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

Growth rate vs price (PEG)

Greenblatt

Attractive

Top 25% (rank 11%)

Frequently Asked Questions

Is GILEAD SCIENCES, INC. (GILD) a good investment?
Based on AlphaStocks' composite analysis, GILEAD SCIENCES, INC. (GILD) scores 6.0 out of 10, earning a Consider Buy rating. This is a middle-of-the-pack score with no strong signal either way. Trading near estimated fair value.
What is GILEAD SCIENCES, INC.'s Piotroski F-Score?
GILEAD SCIENCES, INC.'s Piotroski F-Score status is Strong. The raw score is 7/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is GILD overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $127, GILD appears undervalued. The stock currently trades 2% below its estimated fair value. Trading near estimated fair value.
How does GILD compare to other Health Care stocks?
GILEAD SCIENCES, INC. ranks #264 out of 1123 stocks in the Health Care sector, placing it in the top 24% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about GILD?
AlphaStocks evaluates GILD using five proven investment models. Piotroski: Strong; Buffett: Strong; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Attractive. These models are combined into a single composite score of 6.0/10.

Similar Stocks

BFAMPARRAZN

Compare GILD with

GILD vs BFAMGILD vs PARRGILD vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer